GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Autobio Diagnostics Co 603658.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

39.21

-1.38%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥4.23bn

FY2016FY2025

Net income

CN¥1.07bn

FY2016FY2025

Free cash flow

CN¥737.4m

FY2016FY2025

Shareholders' equity

CN¥8.93bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥4.23bnCN¥4.47bnCN¥4.44bnCN¥4.44bnCN¥3.77bnCN¥2.98bnCN¥2.68bnCN¥1.93bnCN¥1.40bnCN¥980.2m
Gross profitCN¥2.77bnCN¥2.89bnCN¥2.83bnCN¥2.60bnCN¥2.22bnCN¥1.76bnCN¥1.77bnCN¥1.27bnCN¥944.9mCN¥705.6m
Research and developmentCN¥555.1mCN¥731.9mCN¥656.1mCN¥568.5mCN¥481.0mCN¥342.8mCN¥311.9mCN¥212.7mCN¥142.7mCN¥103.9m
Operating incomeCN¥1.23bnCN¥1.15bnCN¥1.37bnCN¥1.30bnCN¥1.08bnCN¥856.4mCN¥894.2mCN¥629.9mCN¥483.1mCN¥394.4m
Net incomeCN¥1.07bnCN¥1.19bnCN¥1.22bnCN¥1.17bnCN¥973.7mCN¥747.8mCN¥774.2mCN¥562.6mCN¥446.6mCN¥349.8m
Diluted earnings per share1.872.082.101.991.671.341.421.030.810.70

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥12.29bnCN¥11.88bnCN¥11.55bnCN¥10.47bnCN¥9.23bnCN¥8.14bnCN¥4.26bnCN¥2.66bnCN¥2.19bnCN¥1.82bn
Cash and short-term investments—CN¥4.04bnCN¥4.52bnCN¥1.14bnCN¥776.7mCN¥413.4mCN¥257.0mCN¥58.5mCN¥26.9mCN¥56.2m
Total liabilitiesCN¥3.27bnCN¥3.18bnCN¥2.89bnCN¥2.56bnCN¥1.83bnCN¥1.55bnCN¥1.62bnCN¥690.7mCN¥497.8mCN¥176.5m
Debt—CN¥253.0mCN¥367.9mCN¥132.5mCN¥236.1mCN¥200.1mCN¥794.9mCN¥96.9mCN¥39.0m—
Shareholders' equityCN¥8.93bnCN¥8.62bnCN¥8.54bnCN¥7.78bnCN¥7.28bnCN¥6.48bnCN¥2.56bnCN¥1.93bnCN¥1.67bnCN¥1.64bn
Shares outstanding571m574m581m586m584m558m544m548m554m497m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.34bnCN¥1.31bnCN¥1.47bnCN¥1.56bnCN¥1.46bnCN¥994.7mCN¥842.9mCN¥653.7mCN¥481.7mCN¥415.8m
Capital spending−CN¥604.3m−CN¥664.4m−CN¥900.4m−CN¥938.3m−CN¥1.07bn−CN¥1.12bn−CN¥762.1m−CN¥410.2m−CN¥455.2m−CN¥237.4m
Free cash flowCN¥737.4mCN¥644.9mCN¥569.4mCN¥620.1mCN¥395.4m−CN¥120.7mCN¥80.8mCN¥243.6mCN¥26.6mCN¥178.4m
Dividends paid−CN¥726.7m−CN¥623.4m−CN¥479.1m−CN¥418.9m−CN¥383.3m−CN¥387.5m−CN¥336.0m−CN¥305.9m−CN¥424.8m−CN¥3.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.07bnCN¥992.2mCN¥1.10bnCN¥1.07bnCN¥1.06bnCN¥995.9mCN¥1.09bnCN¥1.17bn
Gross profitCN¥722.7mCN¥661.2mCN¥746.7mCN¥699.9mCN¥650.6mCN¥648.1mCN¥662.6mCN¥796.4m
Operating incomeCN¥285.5mCN¥250.9mCN¥261.9mCN¥275.4mCN¥272.3mCN¥303.5mCN¥181.4mCN¥375.0m
Net incomeCN¥260.7mCN¥236.4mCN¥208.5mCN¥288.5mCN¥301.1mCN¥269.9mCN¥238.3mCN¥336.7m
Diluted earnings per share0.460.410.360.500.530.470.410.59
Cash from operations———CN¥435.0mCN¥243.0mCN¥166.0m—CN¥453.0m
Capital spending−CN¥93.0m−CN¥133.0m−CN¥139.0m−CN¥138.0m−CN¥179.0m−CN¥146.0m−CN¥123.0m−CN¥158.0m
Free cash flow———CN¥297.0mCN¥64.0mCN¥20.0m—CN¥295.0m
Total assetsCN¥11.78bnCN¥12.24bnCN¥12.29bnCN¥11.73bnCN¥11.65bnCN¥11.97bnCN¥11.88bnCN¥11.39bn
Cash and short-term investments———CN¥882.9mCN¥888.1mCN¥463.9mCN¥469.0mCN¥832.2m
Debt———CN¥829.9mCN¥113.7mCN¥322.0mCN¥232.4mCN¥253.7m
Shareholders' equityCN¥8.67bnCN¥9.16bnCN¥8.93bnCN¥8.75bnCN¥8.46bnCN¥8.88bnCN¥8.62bnCN¥8.40bn

Financial ratios

Data as of 27 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin65.6%64.6%63.7%58.5%59.0%59.2%—
Operating margin29.1%25.8%30.7%29.2%28.6%28.8%—
Net margin25.3%26.7%27.4%26.3%25.9%25.1%—
Return on equity12.0%13.9%14.3%15.0%13.4%11.5%—
Return on assets8.7%10.1%10.5%11.1%10.5%9.2%—
Free cash flow yield10.1%10.2%12.1%12.7%12.9%11.2%—
Revenue growth-5.5%0.6%0.0%17.9%26.5%11.1%—
Earnings growth-10.6%-1.9%4.3%19.9%30.2%-3.4%—
Current ratio2.40x2.46x2.66x2.89x3.81x4.05x—
Debt to equity—0.03x0.04x0.11x0.01x0.03x0.31x
Equity ratio72.6%72.6%73.9%74.3%78.8%79.6%—
Interest coverage88.16x50.37x53.85x59.11x82.66x28.54x—
R&D as a share of sales13.1%16.4%14.8%12.8%12.8%11.5%—
Buybacks as a share of market value0.5%1.2%0.9%-0.4%-4.7%-2.5%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-1.6%7.3%19.4%
Operating income-1.7%7.5%14.7%
Net income-2.9%7.4%14.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin65.1%63.1%62.0%63.3%
Operating margin27.4%28.7%28.7%30.3%
Net margin26.0%26.4%26.2%27.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings19.021.027.231.133.083.352.136.651.561.3
Price to sales4.85.67.58.28.520.915.110.716.421.9

Dividends and splits

Per share, in the currency the company pays

Paid for 9 years. Last went ex-dividend on 1 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year1.311.261.0520.800.720.6540.6920.615
  • 13-for-10 split · 27 May 2021

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.